[go: up one dir, main page]

DK368588D0 - Bindingsmolekyler med en enkelt plypeptidkaede - Google Patents

Bindingsmolekyler med en enkelt plypeptidkaede

Info

Publication number
DK368588D0
DK368588D0 DK368588A DK368588A DK368588D0 DK 368588 D0 DK368588 D0 DK 368588D0 DK 368588 A DK368588 A DK 368588A DK 368588 A DK368588 A DK 368588A DK 368588 D0 DK368588 D0 DK 368588D0
Authority
DK
Denmark
Prior art keywords
chain
plypeptid
molecule
binding molecules
binding specificity
Prior art date
Application number
DK368588A
Other languages
English (en)
Other versions
DK368588A (da
Inventor
Robert Charles Ladner
Robert Earl Bird
Original Assignee
Genex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genex Corp filed Critical Genex Corp
Publication of DK368588D0 publication Critical patent/DK368588D0/da
Publication of DK368588A publication Critical patent/DK368588A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK368588A 1986-09-02 1988-07-01 Bindingsmolekyler med en enkelt polypeptidkaede DK368588A (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90297186A 1986-09-02 1986-09-02
PCT/US1987/002208 WO1988001649A1 (en) 1986-09-02 1987-09-02 Single polypeptide chain binding molecules
CA000546164A CA1341364C (en) 1986-09-02 1987-09-04 Single polypeptide chain binding molecules

Publications (2)

Publication Number Publication Date
DK368588D0 true DK368588D0 (da) 1988-07-01
DK368588A DK368588A (da) 1988-07-01

Family

ID=25671493

Family Applications (1)

Application Number Title Priority Date Filing Date
DK368588A DK368588A (da) 1986-09-02 1988-07-01 Bindingsmolekyler med en enkelt polypeptidkaede

Country Status (7)

Country Link
EP (1) EP0281604B1 (da)
JP (1) JPH02197A (da)
AT (1) ATE87659T1 (da)
CA (1) CA1341364C (da)
DE (1) DE3785186T2 (da)
DK (1) DK368588A (da)
WO (1) WO1988001649A1 (da)

Families Citing this family (437)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
AU612370B2 (en) * 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1989009825A1 (en) * 1988-04-16 1989-10-19 Celltech Limited Method for producing recombinant dna proteins
US5965405A (en) * 1988-04-16 1999-10-12 Celltech Limited Method for producing Fv fragments in eukaryotic cells
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US6416971B1 (en) 1990-05-15 2002-07-09 E.R. Squibb & Sons, Inc. Soluble single chain T cell receptors
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5843728A (en) * 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
JPH08504320A (ja) * 1992-09-25 1996-05-14 コモンウエルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼーション 標的結合性ポリペプチド
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
EP0909277B2 (en) 1996-06-07 2008-12-24 Poniard Pharmaceuticals, Inc. Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
EP0941345A2 (en) * 1996-09-20 1999-09-15 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
GB9705376D0 (en) * 1997-03-14 1997-04-30 Harris William J Antibody fragment formulations and assay formats for detecting the presence an d concentration of analytes
JP3556459B2 (ja) 1998-03-13 2004-08-18 セイコープレシジョン株式会社 Ｅｌモジュール
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
DK2270052T3 (da) 2001-06-26 2018-07-02 Amgen Inc Antistoffer mod OPGL
CA2898314A1 (en) 2001-07-19 2003-07-31 Perian Therapeutics, Inc. Multimeric proteins and methods of making and using same
EP1494714A4 (en) 2002-04-05 2008-03-05 Amgen Inc HUMAN ANTI-OPGL NEUTRALIZING ANTIBODIES AS SELECTIVE OPGL PATH HEMMER
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
EP1498133A1 (en) 2003-07-18 2005-01-19 Aventis Pharma Deutschland GmbH Use of a pak inhibitor for the treatment of a joint disease
ES2523837T3 (es) 2003-07-18 2014-12-01 Amgen Inc. Agentes de unión específica al factor de crecimiento de hepatocitos
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
ES2339710T5 (es) 2003-09-23 2017-10-05 University Of North Carolina At Chapel Hill Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K
AU2004283246B2 (en) 2003-10-14 2009-07-23 Baxalta GmbH Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives
JP5912211B2 (ja) 2004-01-20 2016-04-27 メルス ビー．ヴィー． 結合タンパク質の混合物
US8318905B2 (en) 2004-04-23 2012-11-27 Richard Kroczek Antibodies for depletion of ICOS-positive cells in vivo
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
CA2574881C (en) 2004-08-04 2013-01-08 Amgen Inc. Antibodies to dkk-1
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2006074228A1 (en) 2005-01-07 2006-07-13 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 )
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
DK1861711T3 (da) 2005-03-11 2012-04-16 Sanofi Sa Anvendelse af MGC4504
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
KR101443050B1 (ko) 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
WO2006119905A1 (en) 2005-05-11 2006-11-16 Sanofi-Aventis Use of a gip promoter polymorphism
WO2006124699A2 (en) 2005-05-12 2006-11-23 Wisconsin Alumni Research Foundation Blockade of pin1 prevents cytokine production by activated immune cells
EP2397497A3 (en) 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
ES2333260T3 (es) 2005-09-01 2010-02-18 Schering Corporation Uso de antagonistas de il-23 e il-17 para tratar la enfermedad inflamatoria ocular autoinmunologica.
DE102005048898A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
EP1963369B1 (en) 2005-11-28 2013-05-15 Zymogenetics, Inc. Il-21 antagonists
CA2634080A1 (en) 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
BRPI0706487A2 (pt) 2006-01-10 2011-03-29 Zymogenetics Inc métodos de tratamento de inflamação em tecido neuronal de um mamìfero, de tratamento de dor em um mamìfero, de antagonizar transdução de sinal induzida por il-31 em células de gánglio da raiz dorsal, de tratamento de sintomas associados com queimadura, de tratamento de sintomas associados com infecção viral em um mamìfero, e, de tratamento de dor associada com doença intestinal inflamatória
WO2007087673A1 (en) 2006-02-01 2007-08-09 Arana Therapeutics Limited Domain antibody construct
US20070218065A1 (en) 2006-03-10 2007-09-20 Jaspers Stephen R Antibodies that bind both il-17a and il-17f and methods of using the same
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
EP2412383A1 (en) 2006-07-28 2012-02-01 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
RU2009111884A (ru) 2006-09-01 2010-10-10 Займоджинетикс, Инк. (Us) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
CN103351437A (zh) 2006-11-17 2013-10-16 诺瓦提斯公司 Lingo结合分子及其制药用途
ZA200904022B (en) 2006-12-08 2010-08-25 Lexicon Pharmaceuticals Inc Monoclonal antibodies against ANGPTL3
US20100135998A1 (en) 2007-02-28 2010-06-03 Schering Corporation Combination therapy for treatment of immune disorders
EP2392597B1 (en) 2007-04-27 2014-04-02 ZymoGenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CA2958672A1 (en) 2007-06-15 2008-12-18 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Treatment of tumors using specific anti-l1 antibody
ME02093B (me) 2007-06-18 2014-04-30 N V Organon Antitijela za humani receptor programirane smrti pd-1
EP2023144A1 (en) 2007-08-01 2009-02-11 Sanofi-Aventis Novel AS160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
EA201591355A1 (ru) 2007-08-21 2016-04-29 Амген Инк. АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА
EP4248976A3 (en) 2007-08-23 2024-04-10 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
BRPI0816785A2 (pt) 2007-09-14 2017-05-02 Adimab Inc bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
CA2704357C (en) 2007-11-02 2016-06-21 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use thereof
WO2009064944A2 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
WO2009079212A2 (en) 2007-12-03 2009-06-25 Carnegie Mellon University Linked peptide fluorogenic biosensors
WO2009071696A2 (en) 2007-12-07 2009-06-11 Zymogenetics, Inc. Humanized antibody molecules specific for il-31
EP2105742A1 (en) 2008-03-26 2009-09-30 Sanofi-Aventis Use of cathepsin C
US9441034B2 (en) 2008-03-27 2016-09-13 Zymogenetics, Inc. Compositions and methods for inhibiting PDGFRβ and VEGF-A
US8961991B2 (en) 2009-03-10 2015-02-24 Baylor Research Institute Anti-CD40 targeted fusion proteins
BRPI0918947A2 (pt) 2008-09-26 2015-12-01 Ucb Pharma Sa proteína de fusão de anticorpo
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2219029A1 (en) 2009-01-30 2010-08-18 Sanofi-Aventis Test systems, methods and uses involving AS160 protein
ES2573404T3 (es) 2009-03-02 2016-06-07 Aduro Biotech Holdings, Europe B.V. Anticuerpos contra un ligando inductor de proliferación (APRIL)
CA3032548C (en) 2009-03-10 2023-05-09 Baylor Research Institute Anti-cd40 antibodies and uses thereof
ES2622228T3 (es) 2009-03-10 2017-07-06 Baylor Research Institute Vacunas antivíricas dirigidas a células presentadoras de antígenos
EP2408814B1 (en) 2009-03-20 2018-11-21 Amgen Inc. Carrier immunoglobulins and uses thereof
US8921281B2 (en) 2009-05-20 2014-12-30 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
US8563694B2 (en) 2009-07-31 2013-10-22 Medarex, Inc. Fully human antibodies to BTLA
EP2293072A1 (en) 2009-08-31 2011-03-09 Sanofi-Aventis Use of cathepsin H
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
JP5888728B2 (ja) 2009-11-05 2016-03-22 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
JP2013511279A (ja) 2009-11-20 2013-04-04 アムジエン・インコーポレーテツド 抗Ｏｒａｉ１抗原結合蛋白及びその使用
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
US9995679B2 (en) 2010-05-25 2018-06-12 Carnegie Mellon University Targeted probes of cellular physiology
DK2575881T3 (da) 2010-05-28 2017-01-09 Inst Nat Sante Rech Med Specifikke anti-CD160-antilegemer for behandling af øjensygdomme på grundlag af neoangiogenese
JP6023706B2 (ja) 2010-07-09 2016-11-09 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ２７に対するアゴニスト抗体
BR112013001175A2 (pt) 2010-07-16 2017-07-04 Adimab Llc bibliotecas de anticorpos
WO2012021648A1 (en) 2010-08-10 2012-02-16 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
JP6159660B2 (ja) 2010-09-22 2017-07-05 アムジエン・インコーポレーテツド 担体としての免疫グロブリンおよびその使用
TWI636993B (zh) 2010-10-27 2018-10-01 安美基公司 Ｄｋｋ１抗體及使用方法
US11066483B2 (en) 2010-11-30 2021-07-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
UY33807A (es) 2010-12-17 2012-07-31 Sanofi Sa miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis
TW201241179A (en) 2010-12-17 2012-10-16 Sanofi Sa MiRNAs in joint disease
TW201238974A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
TW201239097A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
WO2012088222A2 (en) 2010-12-21 2012-06-28 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
EP2668207A4 (en) 2011-01-24 2015-06-10 Univ Singapore MANNOSE-CAPTURED LIPOARABINOMANANE ANTIGEN-BINDING PROTEINS OBTAINED FROM ILLNESSIFYING MYCOBACTERIES
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
SG193434A1 (en) 2011-03-16 2013-10-30 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
US20120301465A1 (en) 2011-03-25 2012-11-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods to immunize against hepatitis c virus
SG193552A1 (en) 2011-03-30 2013-11-29 Boehringer Ingelheim Int Anticoagulant antidotes
CN103619881B (zh) 2011-04-07 2017-07-28 安姆根有限公司 新的egfr结合蛋白
KR101338517B1 (ko) 2011-04-18 2013-12-10 연세대학교 산학협력단 인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도
EP2518157A1 (en) 2011-04-26 2012-10-31 Sanofi Test Systems and methods for identifying a compound altering cellular DDR activity
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP2537532A1 (en) 2011-06-22 2012-12-26 J. Stefan Institute Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
TW201329104A (zh) 2011-12-08 2013-07-16 Amgen Inc 人類ｌｃａｔ抗原結合蛋白質及其治療用途
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
PL3431492T3 (pl) 2012-04-27 2021-07-05 Novo Nordisk A/S Białka wiążące antygen ludzkiego ligandu CD30
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
EP2859114B1 (en) 2012-06-11 2019-05-15 Amgen, Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
DK2922872T3 (da) 2012-11-21 2019-01-02 Janssen Biotech Inc Bispecifikke egfr/c-met-antistoffer
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US9676851B2 (en) 2013-03-15 2017-06-13 Amgen Inc. Human PAC1 antibodies
CA2904722C (en) 2013-03-15 2023-01-03 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
WO2014151422A1 (en) 2013-03-15 2014-09-25 Janssen Biotech, Inc. Interferon alpha and omega antibody antagonists
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
JP6267792B2 (ja) 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
RU2016107426A (ru) 2013-08-02 2017-09-07 Адуро Байотек Холдингс, Юроуп Б.В. Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
CN105555291B (zh) 2013-08-07 2021-08-24 助育公司 用于治疗雄性不育症的抗体、化合物及其衍生物
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
AU2014317009A1 (en) 2013-09-05 2016-03-10 Aduro Biotech Holdings, Europe B.V. CD70-binding peptides and method, process and use relating thereto
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
EA034655B1 (ru) 2013-11-06 2020-03-03 Янссен Байотек, Инк. Антитела к ccl17
US10023636B2 (en) 2013-12-20 2018-07-17 Intervet Inc. Caninized murine antibodies to human PD-1
CN106062005A (zh) 2013-12-30 2016-10-26 医药生命融合研究团 抗krs单克隆抗体及其用途
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
EP3992210A1 (en) 2014-01-13 2022-05-04 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
AP2017009765A0 (en) 2014-08-19 2017-02-28 Merck Sharp & Dohme Anti-tigit antibodies
KR102586588B1 (ko) 2014-09-09 2023-10-06 얀센 바이오테크 인코포레이티드 항-cd38 항체를 사용하는 병용 요법
CN107429075B (zh) 2014-11-17 2022-11-01 卡内基梅隆大学 可激活的双组份光敏剂
EP3783031B1 (en) 2014-12-03 2023-08-02 Aimed Bio Inc. Antibody against neuropilin 1 and use thereof
US10357563B2 (en) 2014-12-18 2019-07-23 The University Of Chicago Methods and composition for neutralization of influenza
CA2971734A1 (en) 2014-12-22 2016-06-30 Enumeral Biomedical Holdings, Inc. Anti-pd-1 antibodies
EP3085709B1 (en) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
EP3244911B1 (en) 2015-01-12 2019-10-23 Rigshospitalet, Copenhagen University Hospital A method for determining a likely effect of a treatment to improve male infertility
SI3253865T1 (sl) 2015-02-06 2022-10-28 National University Of Singapore Postopki za izboljšanje učinkovitosti terapevtskih imunskih celic
AU2016226069A1 (en) 2015-03-04 2017-09-21 The University Of Chicago Beta-catenin inhibitors in cancer immunotherapy
EP3277722B1 (en) 2015-04-02 2021-08-18 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
MY198983A (en) 2015-05-20 2023-10-06 Janssen Biotech Inc Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
KR20240059639A (ko) 2015-06-01 2024-05-07 더 유니버서티 오브 시카고 공생 미생물총의 조작에 의한 암의 치료
WO2016209921A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20160376373A1 (en) 2015-06-24 2016-12-29 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
CN114605549A (zh) 2015-08-05 2022-06-10 詹森生物科技公司 抗cd154抗体及其使用方法
CN109069622A (zh) 2015-09-30 2018-12-21 詹森生物科技公司 特异性结合人cd40的拮抗性抗体和使用方法
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
SMT202100192T1 (it) 2015-11-03 2021-05-07 Janssen Biotech Inc Formulazioni sottocutanee di anticorpi anti-cd38 e loro usi.
BR112018008867A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e seus usos
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
KR101896882B1 (ko) 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
CA3008244A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
KR20180087430A (ko) 2015-12-17 2018-08-01 얀센 바이오테크 인코포레이티드 Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
MY197023A (en) 2015-12-23 2023-05-22 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
US20170198290A1 (en) 2016-01-08 2017-07-13 Northwestern University Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (klc1c)
US11028410B2 (en) 2016-01-27 2021-06-08 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
AU2017216230B2 (en) 2016-02-03 2023-07-06 Amgen Inc. BCMA and CD3 bispecific T cell engaging antibody constructs
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
MX2018009386A (es) 2016-02-03 2018-11-09 Amgen Res Munich Gmbh Constructos de anticuerpo biespecificos para psma y cd3 que se ligan a celulas t.
CA3013584C (en) 2016-02-15 2021-01-12 Samsung Life Public Welfare Foundation Antibody against egfrviii and use thereof
RU2746754C2 (ru) 2016-03-14 2021-04-20 Чугаи Сейяку Кабусики Кайся Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
ES2891578T3 (es) 2016-04-01 2022-01-28 Kite Pharma Inc Antígeno quimérico y receptores de células T y métodos de uso
KR102608405B1 (ko) 2016-04-01 2023-12-01 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
IL262061B2 (en) 2016-04-01 2023-03-01 Amgen Inc Chimeric flt-3 receptors and methods of using them
TWI761831B (zh) 2016-04-01 2022-04-21 美商凱特製藥公司 嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途
CA3019588A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
BR112018072986A2 (pt) 2016-05-18 2019-03-06 Boehringer Ingelheim International Gmbh anticorpos anti-pd-1 e anti-lag3 para tratamento de câncer
MX2018014554A (es) 2016-05-27 2019-09-09 Orum Therapeutics Inc Anticuerpo penetrante de citosol y uso del mismo.
WO2017209554A2 (ko) 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 항-nrp1 항체 스크리닝 방법
JP6895460B2 (ja) 2016-06-03 2021-06-30 アイメッド・バイオ・インコーポレイテッド 患者由来腫瘍スフェロイドを用いた抗体スクリーニング方法
AU2017273170B2 (en) 2016-06-03 2020-08-27 Aimed Bio Inc. Anti-NRP1 antibody screening method
WO2017209553A2 (ko) 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 환자 유래 세포를 이용한 항체 스크리닝 방법
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
US10478497B2 (en) 2016-07-20 2019-11-19 Hybrigenics S.A. Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018026249A1 (ko) 2016-08-05 2018-02-08 주식회사 와이바이오로직스 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도
CA3032783C (en) 2016-08-05 2022-05-31 Y-Biologics Inc. Antibody to programmed cell death 1 (pd-1) and use thereof
CA3032806C (en) 2016-08-05 2021-04-27 Y-Biologics Inc. Antibody to programmed death-ligand 1 (pd-l1) and use thereof
SG11201900744SA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
KR102587941B1 (ko) 2016-08-12 2023-10-11 얀센 바이오테크 인코포레이티드 향상된 효능작용 및 이펙터 기능을 갖는 조작된 항체 및 다른 Fc-도메인 함유 분자
WO2018057915A1 (en) 2016-09-23 2018-03-29 The Regents Of The University Of Michigan Engineered lymphocytes
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018067754A1 (en) 2016-10-04 2018-04-12 Fairbanks Pharmaceuticals, Inc. Anti-fstl3 antibodies and uses thereof
EP3532101B1 (en) 2016-10-28 2021-12-08 Astute Medical, Inc. Use of antibodies to timp-2 for the improvement of renal function
CA3041717A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
CA3045857A1 (en) 2016-12-22 2018-06-28 Universita Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
CN106519034B (zh) 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
US11111292B2 (en) 2016-12-23 2021-09-07 Cephalon, Inc. Anti-IL-5 antibodies
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
EP3580563A4 (en) 2017-02-09 2020-11-18 Promega Corporation ANALYTE DETECTION IMMUNOLOGICAL ASSAY
US10857230B2 (en) 2017-03-03 2020-12-08 Janssen Biotech, Inc. Co-therapy comprising a small molecule CSF-1R inhibitor and an agonistic antibody that specifically binds CD40 for the treatment of cancer
IL315837A (en) 2017-04-13 2024-11-01 Sairopa B V Anti-SIRP-alpha antibodies
UY37726A (es) 2017-05-05 2018-11-30 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
US11479612B2 (en) 2017-05-30 2022-10-25 Chong Kun Dang Pharmaceutical Corp. Anti-c-Met antibody and use thereof
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
CN110785185B (zh) 2017-06-05 2024-05-24 詹森生物科技公司 具有非对称ch2-ch3区突变的工程化多特异性抗体和其他多聚体蛋白
US11638728B2 (en) 2017-06-05 2023-05-02 The University Of Chicago Microbiome biomarkers immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof
EP3634995A4 (en) 2017-06-05 2021-06-09 Janssen Biotech, Inc. ANTIBODIES BINDING SPECIFICALLY TO PD-1 AND THEIR METHODS OF USE
PE20200013A1 (es) 2017-06-20 2020-01-06 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
EP3642238A1 (en) 2017-06-21 2020-04-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
EP4464719A3 (en) 2017-08-04 2025-03-05 Amgen Inc. Method of conjugation of cys-mabs
US11078263B2 (en) 2017-08-25 2021-08-03 Janssen Biotech, Inc. Fc γ RIII binding fibronectin type III domains, their conjugates and multispecific molecules comprising them
CN114533863A (zh) 2017-09-15 2022-05-27 凯德药业股份有限公司 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
EP3692061A1 (en) 2017-10-04 2020-08-12 Amgen Inc. Transthyretin immunoglobulin fusions
CA3077085A1 (en) 2017-10-06 2019-04-11 Oncotherapy Science, Inc. Screening of t lymphocytes for cancer-specific antigens
CN112105380A (zh) 2017-10-11 2020-12-18 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体和其用途
SG11202003585VA (en) 2017-10-20 2020-05-28 Pharmabcine Inc Anti-vista antibody and use thereof
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
JP7183268B2 (ja) 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
AR113491A1 (es) 2017-12-11 2020-05-06 Amgen Inc Proceso de elaboración continuo para productos de anticuerpos biespecíficos
KR102311838B1 (ko) 2017-12-27 2021-10-14 주식회사 파멥신 항-pd-l1 항체 및 이의 용도
TWI817974B (zh) 2017-12-28 2023-10-11 日商中外製藥股份有限公司 細胞毒性誘導治療劑
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
US20190225689A1 (en) 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies
WO2019147822A2 (en) 2018-01-24 2019-08-01 Northwestern University Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (klc1c)
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US11702464B2 (en) 2018-03-02 2023-07-18 The University Of Chicago Methods and composition for neutralization of influenza
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
KR102275930B1 (ko) 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
US20190284288A1 (en) 2018-03-19 2019-09-19 The Regents Of The University Of Michigan Compositions and methods for t-cell and cytokine activation
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
US12012462B2 (en) 2018-04-10 2024-06-18 Amgen Inc. Chimeric receptors to DLL3 and methods of use thereof
US11884725B2 (en) 2018-04-24 2024-01-30 Ampsource Biopharma Shanghai Inc. Antibody against TIM-3 and application thereof
CN112469826B (zh) 2018-04-27 2024-02-09 (株)爱恩德生物 通过磁珠附着至细胞进行的基于磁性的生物淘选方法
US20220089756A1 (en) 2018-05-08 2022-03-24 Amgen Inc. Bispecific antibodies with cleavable c-terminal charge-paired tags
BR112020023187A2 (pt) 2018-05-16 2021-04-20 Janssen Biotech, Inc. métodos para tratamento de cânceres e de aumento da eficácia de agentes terapêuticos de redirecionamento de células t
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
SG11202010996QA (en) 2018-05-23 2020-12-30 Nat Univ Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
JOP20200295A1 (ar) 2018-05-24 2020-11-22 Janssen Biotech Inc أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها
KR20210015902A (ko) 2018-05-24 2021-02-10 얀센 바이오테크 인코포레이티드 Psma 결합제 및 이의 용도
BR112020023508A2 (pt) 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
KR102115300B1 (ko) 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
US11945864B2 (en) 2018-06-29 2024-04-02 Y-Biologics Inc. Monoclonal antibody specifically binding to LAG-3 and use thereof
KR20210033025A (ko) 2018-07-18 2021-03-25 암젠 인크 Steap1에 대한 키메라 수용체 및 이의 사용 방법
KR20210041586A (ko) 2018-08-01 2021-04-15 세파론, 인코포레이티드 항-cxcr2 항체 및 이의 용도
CA3106829A1 (en) 2018-08-03 2020-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
EP3835320A4 (en) 2018-08-10 2022-06-01 Eutilex Co., Ltd. Chimeric antigen receptor binding to hla-dr, and car-t cell
US20210236599A1 (en) 2018-08-13 2021-08-05 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
RS65658B1 (sr) 2018-08-27 2024-07-31 Affimed Gmbh Kriokonzervirane nk ćelije prethodno punjene konstruktom antitela
CA3109366A1 (en) 2018-09-13 2020-03-19 The Board Of Regents Of The University Of Texas System Novel lilrb4 antibodies and uses thereof
WO2020077212A1 (en) 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
WO2020081881A2 (en) 2018-10-17 2020-04-23 Janssen Biotech, Inc. Method of providing subcutaneous administration of anti-cd38 antibodies
PE20211867A1 (es) 2018-11-01 2021-09-21 Shandong New Time Pharmaceutical Co Ltd Anticuerpos biespecificos y su uso
US11634499B2 (en) 2018-11-13 2023-04-25 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
EP3887830A2 (en) 2018-11-28 2021-10-06 Promega Corporation Reactive peptide labeling
AU2019412405B2 (en) 2018-12-27 2024-07-25 Akeso Biopharma, Inc Antibody against human IL-4RA and use thereof
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CA3126727A1 (en) 2019-01-28 2020-08-06 Maple Biotech Llc Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
WO2020163448A1 (en) 2019-02-06 2020-08-13 The Regents Of The University Of Michigan Chimeric antigen receptors targeting abnormal glycobiology
WO2020168059A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
BR112021014582A2 (pt) 2019-02-15 2021-10-05 Just-Evotec Biologics, Inc. Sistemas, instalações e processos de biomanufatura automatizados
CN113661175A (zh) 2019-02-15 2021-11-16 整体分子公司 包含共同轻链的抗体及其用途
US20220118089A1 (en) 2019-02-25 2022-04-21 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
BR112021016149A2 (pt) 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
EP3936150A4 (en) 2019-03-06 2023-03-29 LegoChem Biosciences, Inc. ANTIBODY-DRUG CONJUGATES COMPRISING ANTIBODY AGAINST HUMAN DLK1 AND USE THEREOF
US11541086B2 (en) 2019-03-14 2023-01-03 Northwestern Univeristy Compositions and methods for treating Alzheimer's disease
WO2020191339A1 (en) 2019-03-20 2020-09-24 Promega Corporation Photoaffinity probes
MX2021012765A (es) 2019-04-19 2021-11-18 Janssen Biotech Inc Metodos para tratar el cancer renal con un anticuerpo anti-psma/cd3.
BR112021020532A2 (pt) 2019-04-19 2022-03-15 Janssen Biotech Inc Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
PH12021552798A1 (en) 2019-05-14 2022-09-19 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
CN114206355A (zh) 2019-06-03 2022-03-18 芝加哥大学 用靶向癌症的佐剂治疗癌症的方法和组合物
MX2021014433A (es) 2019-06-05 2022-03-11 Chugai Pharmaceutical Co Ltd Molecula de union a sitio de escision de anticuerpo.
WO2020252442A1 (en) 2019-06-13 2020-12-17 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
KR20220041080A (ko) 2019-06-18 2022-03-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
CN114206379A (zh) 2019-06-18 2022-03-18 爱尔兰詹森科学公司 乙型肝炎病毒(hbv)疫苗和抗pd-1抗体的组合
WO2021007150A1 (en) 2019-07-08 2021-01-14 Amgen Inc. Multispecific transthyretin immunoglobulin fusions
EP3997230A4 (en) 2019-07-10 2023-08-02 Chugai Seiyaku Kabushiki Kaisha CLAUDIN-6 BINDING MOLECULES AND THEIR USES
EP3999538A1 (en) 2019-07-15 2022-05-25 Intervet International B.V. Caninized antibodies against canine ctla-4
KR20220038775A (ko) 2019-07-30 2022-03-29 아케소 바이오파마, 인크. 항-인간 p40 단백질 도메인 항체 및 이의 용도
WO2021043220A1 (zh) 2019-09-03 2021-03-11 中山康方生物医药有限公司 抗cd47的单克隆抗体及其用途
AU2020342910A1 (en) 2019-09-04 2022-04-07 Pierre Fabre Medicament Anti-VSIG4 antibody or antigen binding fragment and uses thereof
AU2020345787A1 (en) 2019-09-10 2022-03-24 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
JP2022550067A (ja) 2019-09-27 2022-11-30 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｅａｃａｍ抗体及びその使用
TW202128756A (zh) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
EP4045044A1 (en) 2019-10-18 2022-08-24 The Regents Of The University Of California Plxdc activators and their use in the treatment of blood vessel disorders
CA3160302A1 (en) 2019-11-07 2021-05-14 Amgen Inc. Method of treating or ameliorating cushing's syndrome using binding proteins for gastric inhibitory peptide receptor (gipr)
US20220396599A1 (en) 2019-11-13 2022-12-15 Amgen Inc. Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
WO2021099906A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
US12241839B2 (en) 2019-11-27 2025-03-04 Promega Corporation Multipartite luciferase peptides and polypeptides
WO2021110561A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins for use in treating hepatitis b infection
KR20220109436A (ko) 2019-12-03 2022-08-04 에보텍 인터내셔널 게엠베하 인터페론-결합된 항원 결합 단백질 및 이의 용도
EP4073512A1 (en) 2019-12-10 2022-10-19 Promega Corporation Compositions and methods for bioluminescent detection using multifunctional probes
KR20230015874A (ko) 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202140012A (zh) 2020-02-12 2021-11-01 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
AU2021240028A1 (en) 2020-03-19 2022-09-15 Amgen Inc. Antibodies against mucin 17 and uses thereof
CA3173519A1 (en) 2020-03-31 2021-10-07 Vishnu Priyanka Reddy CHICHILI Method for producing multispecific antigen-binding molecules
EP4130732A4 (en) 2020-04-02 2024-06-19 Chugai Seiyaku Kabushiki Kaisha METHOD FOR ANALYZING IMPURITIES MOLECULES IN A COMPOSITION CONTAINING MULTI-SPECIFIC ANTIGEN BINDING MOLECULES
US20230183354A1 (en) 2020-04-30 2023-06-15 Sairopa B.V. Anti-cd103 antibodies
AU2021272291A1 (en) 2020-05-11 2023-02-02 Janssen Biotech, Inc. Methods for treating multiple myeloma
EP4153316A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer
AU2021275049A1 (en) 2020-05-19 2022-12-22 Amgen Inc. MAGEB2 binding constructs
US20210363252A1 (en) 2020-05-19 2021-11-25 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
WO2021247908A1 (en) 2020-06-03 2021-12-09 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
CN116390772A (zh) 2020-07-07 2023-07-04 博泰康医药公司 新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途
KR20230048059A (ko) 2020-07-31 2023-04-10 추가이 세이야쿠 가부시키가이샤 키메라 수용체를 발현하는 세포를 포함하는 의약 조성물
WO2022023292A2 (en) 2020-07-31 2022-02-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Corona virus spike protein-targeting antibodies and use thereof
MX2023002980A (es) 2020-09-14 2023-06-06 Janssen Pharmaceutica Nv Terapias de combinación de inhibidores del fgfr.
CN116322769A (zh) 2020-09-16 2023-06-23 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
IL300314A (en) 2020-10-08 2023-04-01 Affimed Gmbh Coupling materials with triple specificity
WO2022084355A2 (en) 2020-10-21 2022-04-28 Boehringer Ingelheim International Gmbh Agonistic trkb binding molecules for the treatment of eye diseases
CR20230229A (es) 2020-11-06 2023-09-05 Amgen Res Munich Gmbh Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
JP2024507220A (ja) 2021-02-19 2024-02-16 セリピオン， インコーポレイテッド パラオキソナーゼ融合ポリペプチドならびに関連する組成物および方法
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
WO2022189942A1 (en) 2021-03-09 2022-09-15 Janssen Biotech, Inc. Treatment of cancers lacking egfr-activating mutations
AU2022246675A1 (en) 2021-04-02 2023-10-19 Amgen Inc. Mageb2 binding constructs
US20240043531A1 (en) 2021-04-14 2024-02-08 Akeso Biopharma, Inc. Anti-cd47 monoclonal antibody and use thereof
TW202308689A (zh) 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
IL307672A (en) 2021-05-06 2023-12-01 Amgen Res Munich Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
KR20240008345A (ko) 2021-05-18 2024-01-18 얀센 바이오테크 인코포레이티드 T 세포 재유도 치료제 및 항-cd44 치료제를 포함하는 조성물
TW202309094A (zh) 2021-05-18 2023-03-01 美商健生生物科技公司 用於識別癌症患者以進行組合治療之方法
JP2024518844A (ja) 2021-05-20 2024-05-07 ダイアンサス セラピューティクス オプコ， インコーポレイテッド Ｃ１ｓに結合する抗体およびその使用
CA3218786A1 (en) 2021-05-25 2022-12-01 Lifei HOU C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
CN117999085A (zh) 2021-06-09 2024-05-07 埃沃特克国际有限责任公司 用于治疗或预防冠状病毒感染的干扰素相关的抗原结合蛋白
EP4355778A1 (en) 2021-06-17 2024-04-24 Boehringer Ingelheim International GmbH Novel tri-specific binding molecules
CN115558023A (zh) 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 抗cd3抗体及其用途
WO2023287707A1 (en) 2021-07-15 2023-01-19 Just-Evotec Biologics, Inc. Bidirectional tangential flow filtration (tff) perfusion system
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
CN117751144A (zh) 2021-08-02 2024-03-22 杭州优诺健生物科技有限公司 抗cd38抗体、抗cd3抗体和双特异性抗体以及它们的用途
WO2023015169A1 (en) 2021-08-02 2023-02-09 Tavotek Biotech (Suzhou) Ltd Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
JPWO2023053282A1 (da) 2021-09-29 2023-04-06
JP2024538148A (ja) 2021-10-18 2024-10-18 タボテック バイオセラピューティクス（ホンコン）リミティド 抗ＥＧＦＲ抗体、抗ｃＭＥＴ抗体、抗ＶＥＧＦ抗体、多重特異性抗体及びそれらの使用
EP4423125A1 (en) 2021-10-29 2024-09-04 Zielbio, Inc. Cancer specific plectin-1 specific antibodies and methods of use thereof
KR20240099376A (ko) 2021-11-03 2024-06-28 얀센 바이오테크 인코포레이티드 암 치료 및 bcmaxcd3 이중특이성 항체의 효능을 향상시키는 방법
MX2024005397A (es) 2021-11-03 2024-05-23 Affimed Gmbh Agentes de union a cd16a biespecificos.
EP4426439A1 (en) 2021-11-03 2024-09-11 Affimed GmbH Bispecific cd16a binders
EP4426435A1 (en) 2021-11-03 2024-09-11 Janssen Biotech, Inc. Corticosteriod reduction in treatment with anti-cd38 antibodies
CA3236923A1 (en) 2021-11-09 2023-05-19 Amgen Inc. Method of producing an antibody peptide conjugate
US20230183360A1 (en) 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
AU2022409802A1 (en) 2021-12-15 2024-06-06 Interius Biotherapeutics, Inc. Pseudotyped viral particles, compositions comprising the same, and uses thereof
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
AU2023259287A1 (en) 2022-04-29 2024-12-12 Akeso Biopharma, Inc Anti-human il-4ra antibody and application thereof
WO2023215514A2 (en) 2022-05-04 2023-11-09 Promega Corporation Bioluminescence-triggered photocatalytic labeling
KR20250011917A (ko) 2022-05-12 2025-01-22 암젠 리서치 (뮌헨) 게엠베하 증가된 선택성의 다중쇄 다중표적화 이중특이적 항원 결합 분자
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
US20240076343A1 (en) 2022-06-16 2024-03-07 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
CN117285632A (zh) 2022-06-17 2023-12-26 安源医药科技（上海）有限公司 针对tfpi的单克隆抗体及其用途
US20240317866A1 (en) 2022-06-30 2024-09-26 Janssen Biotech, Inc. Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer
IL317689A (en) 2022-07-15 2025-02-01 Boehringer Ingelheim Int Binding molecules for cancer treatment
IL317811A (en) 2022-07-25 2025-02-01 Interius Biotherapeutics Inc Mutated polypeptides, compositions containing them and uses thereof
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024228717A2 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. Fentanyl-specific single variable-domain antibodies and use in a continuous agglutination assay
AU2023343470A1 (en) 2022-09-14 2025-02-06 Amgen Inc. Bispecific molecule stabilizing composition
WO2024079711A1 (en) 2022-10-14 2024-04-18 Janssen Research & Development, Llc Method for detection of antibody-dependent cellular phagocytosis
WO2024084461A1 (en) 2022-10-21 2024-04-25 Janssen Research & Development, Llc Methods and systems for microbial detection using raman spectroscopy
WO2024084460A1 (en) 2022-10-21 2024-04-25 Janssen Research & Development, Llc Methods for microbial detection
WO2024084463A1 (en) 2022-10-21 2024-04-25 Janssen Research & Development, Llc Methods and systems for microbial detection using infrared spectroscopy
WO2024092240A1 (en) 2022-10-28 2024-05-02 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
WO2024095173A1 (en) 2022-11-02 2024-05-10 Janssen Biotech, Inc. Methods of treating cancers
WO2024102962A1 (en) 2022-11-10 2024-05-16 Immuvia Inc Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
WO2024112734A1 (en) 2022-11-21 2024-05-30 Dianthus Therapeutics Opco, Inc. Antibodies that bind to c1s and uses thereof
US12049502B2 (en) 2022-11-30 2024-07-30 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
WO2024126293A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
WO2024126289A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
WO2024126294A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024151213A2 (en) 2023-01-12 2024-07-18 National University Of Singapore Blockade of cd8 expression and chimeric antigen receptors for immunotherapy of t-cell and nk-cell malignancies
WO2024170486A1 (en) 2023-02-13 2024-08-22 Intervet International B.V. Canine antibodies to canine il-4
WO2024170485A1 (en) 2023-02-13 2024-08-22 Intervet International B.V. Canine antibodies to canine il-13
US20240392027A1 (en) 2023-02-28 2024-11-28 Janssen Biotech Inc. Compositions comprising a bispecific gprc5d/cd3 antibody
WO2024187062A1 (en) 2023-03-08 2024-09-12 Amgen Inc. Controlled-ice nucleation lyophilization process for bispecific molecules
WO2024189544A1 (en) 2023-03-13 2024-09-19 Janssen Biotech, Inc. Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
WO2024213635A1 (en) 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
WO2024231860A1 (en) 2023-05-09 2024-11-14 Janssen Biotech, Inc. Pharmaceutical compositions comprising a bispecific bcma/cd3 antibody at high concentration
WO2024241273A1 (en) 2023-05-23 2024-11-28 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
WO2024246856A1 (en) 2023-06-01 2024-12-05 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2024259378A1 (en) 2023-06-14 2024-12-19 Amgen Inc. T cell engager masking molecules
WO2025014773A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
WO2025050009A2 (en) 2023-09-01 2025-03-06 Children's Hospital Medical Center Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988006630A1 (en) * 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
AU612370B2 (en) * 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins

Also Published As

Publication number Publication date
DE3785186T2 (de) 1993-07-15
EP0281604A1 (en) 1988-09-14
EP0281604A4 (en) 1990-01-08
WO1988001649A1 (en) 1988-03-10
ATE87659T1 (de) 1993-04-15
CA1341364C (en) 2002-06-04
EP0281604B1 (en) 1993-03-31
DE3785186D1 (de) 1993-05-06
JPH02197A (ja) 1990-01-05
DK368588A (da) 1988-07-01

Similar Documents

Publication Publication Date Title
DK368588D0 (da) Bindingsmolekyler med en enkelt plypeptidkaede
PT87138A (pt) Process for the preparation of adn recombinant molecules codin g polypeptide adn segments and of antibody compositions relate d with human tissue factor
ES2165851T3 (es) Proteinas multivalentes que se unen a antigenos.
DK1015587T3 (da) DcR3 polypeptid, en TNFR-homolog
ES2070172T3 (es) Procedimiento para producir proteinas mediante adn recombinante.
IL193886A0 (en) Antibodies that bind to ldcam sequences
DE69412614D1 (de) Recombinante disulfid-stabilisierte polypeptide mit bindung spezifität
CY1112101T1 (el) Νευροτροφικοι παραγοντες
CY1105161T1 (el) Ομολογα προσδεματος τιε
HRP20090517T1 (en) Interleukin-10 antibodies
ES2184728T3 (es) Proteinas de union a la fibronectina.
DE3783191D1 (de) Verfahren und mittel zur herstellung eines proteins mit der gleichen igg-spezifizitaet wie protein g.
DK346385D0 (da) Genetiske sekvenser, hermed kodede interferon-peptider af type i og organismer, der producerer disse
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
DK0629238T3 (da) Autotaxin:Motilitetsstimulerende protein, som er nyttigt til cancerdiagnose og terapi
DK0789763T3 (da) ICAM-4-materialer og fremgangsmåder
ATE169672T1 (de) Rekombinantes ricin-toxin
DK1105485T3 (da) Human IL-1-epsilon-DNA og polypeptider
EA200200286A1 (ru) Ген prv-1 и его применение
EA200100110A1 (ru) Нейротрофические факторы
AR041564A1 (es) Genes aislados de proteinas de membrana de mamiferos reactivos relacionados

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment
AHS Application shelved for other reasons than non-payment
AHS Application shelved for other reasons than non-payment
AHS Application shelved for other reasons than non-payment
AHS Application shelved for other reasons than non-payment
AHS Application shelved for other reasons than non-payment